Found 29 matching trials
Different Doses of Dalpicicl Combined With Letrozole in the First-line Treatment of HR-positive, HER2-negative Advanced Breast Cancer PHASE2 This study is a prospective, open-label, randomized, multicenter, two-cohor...
Show More Location
The Second Affiliated Hospital of Dalian Medical University
Learn More & Join Trial
Study of Dalpiciclib Combined With Letrozole in the Maintenance Treatment of HR Positive and HER2 Negative Metastatic Breast Cancer After First-line Chemotherapy PHASE2 This study aimed to evaluate the efficacy and safety of Dalpiciclib combine...
Show More Location
West China Hospital, Sichuan University
Learn More & Join Trial
Pyrotinib Combined With Trastuzumab,Dalpiciclib and Letrozole for HR+/HER2+ Breast Cancer PHASE2 In this single arm, open label, phase 2 trial, operable patients with stage...
Show More Location
Yantai Yuhuangding Hospital
Learn More & Join Trial
Chemo-free in Older (โฅ65) Node-Positive ER+/HER2- Breast Cancer PHASE3 This study is a prospective, open-label, multicenter, randomized controlled...
Show More Location
Multiple Locations
Learn More & Join Trial
An Exploratory Clinical Study of CDK4/6i Dalpiciclib Combined With AI Neoadjuvant Therapy for Stage II-III HR+/HER2- Breast Cancer PHASE4 This is a single-arm, open-label, exploratory clinical study...
Location
Multiple Locations
Learn More & Join Trial
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy PHASE2 The purpose of this study is to establish a prospective, single-center plat...
Show More Location
Fudan University Shanghai Cancer Center Shanghai, China, 200032
Learn More & Join Trial
Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study PHASE2 This study is a multicenter, prospective, randomized, open-label clinical s...
Show More Location
Fujian Cancer Hosptial
Learn More & Join Trial
Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES) PHASE3 CDK4/6 inhibitors are currently the standard treatment for female breast ca...
Show More Location
Peking Union Medical College Hospital
Learn More & Join Trial
Neoadjuvant Dalpiciclib Plus Aromatase Inhibitors in Luminal B/HER2-negative Breast Cancer (DANCER) PHASE2 Evaluate the efficacy and safety of Dalpiciclib combined with aromatase inh...
Show More Location
2nd Affiliated Hospital, School of Medicine, Zhejiang University
Learn More & Join Trial
The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis PHASE2 This is a multicenter, single-arm, open-label, Simon's two-stage explorator...
Show More Location
Cancer Hospital, Chinese Academy of Medical Sciences
Learn More & Join Trial